Son of Darzalex hits the skids
J&J decides not to opt in to erzotabart, and Genmab pulls the plug.
ASH 2024 – J&J aims at a myeloma precursor
The Aquila study could make Darzalex the first approved drug for smouldering multiple myeloma.
Regeneron keeps up its co-stimulatory crusade
The company’s CD38 x CD28 MAb is among recent clinical trial entrants.
The month ahead: September’s upcoming events
It’s back to school for biotech, with a packed conference schedule.
Regeneron gets another bispecific blow
Meanwhile, recent updates hint at more issues in the group’s pipeline of bispecific MAbs.
FDA green and red lights: July 2024
Darzalex added another string to its bow, while Kisqali’s early use has been delayed.
